DDrare: Database of Drug Development for Rare Diseases

21. ミトコンドリア病
［臨床試験数：23，薬物数：29（DrugBank：28），標的遺伝子数：44，標的パスウェイ数：65］

Searched query = "Mitochondrial disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Bupropion; Caffeine; CoenzymeQ10; Cysteamine; Cysteamine Bitartrate; Dexmedetomidine; Dextromethorphan; EPI-743; Elamipretide; Elamipretide (high dose); Elamipretide (intermediate dose); Elamipretide (low dose); Flurbiprofen; Fluzone; Fluzone®; KH176; KL1333; Low Residue Diet Intervention; Midazolam; Midazolam injection; Omeprazole; Propofol; RG2133 (2',3',5'-tri-O-acetyluridine); Repaglinide; SPP-004; Sevoflurane; Sonlicromanol; Tri-O-acetyluridine; Vatiquinone

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00060515 (ClinicalTrials.gov)	April 2003	7/5/2003	RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease	An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases	Mitochondrial Diseases	Drug: RG2133 (2',3',5'-tri-O-acetyluridine)	Repligen Corporation	NULL	Terminated	3 Years	N/A	Both	12	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00060515
(ClinicalTrials.gov)

April 2003

7/5/2003

RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases

Mitochondrial Diseases

Drug: RG2133 (2',3',5'-tri-O-acetyluridine)

Repligen Corporation

NULL

Terminated

3 Years

N/A

Both

Phase 1

United States